lba100: the randomized dynamic trial
Published 2 years ago • 226 plays • Length 6:51Download video MP4
Download video MP3
Similar videos
-
1:51
a positive ctdna test after adjuvant therapy: 2023 best of gi
-
1:22
an all-molecular diagnostic approach for myeloma
-
3:59
universal screening for brca1 and brca2 mutations
-
0:54
advances in molecular testing in brain cancer
-
1:37
genomic determinants of response to blinatumomab
-
3:25
understand ctdna testing
-
2:22
ion robot: a new tool to detect lung cancer
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
2:35
quizartinib for frontline flt3-itd aml: updated results from the quantum-first trial
-
5:30
should aml molecular tests be repeated?
-
1:44
cxcr1/2 and pd-1 inhibition in ctdna positive and ras-mutant crc
-
1:45
clinical trial available for women with brca1 mutations to assess reduced risk of ovarian cancer
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
2:43
diagnostic tools for aml
-
5:02
going beyond pd-l1 testing for lung cancer immunotherapy
-
2:46
recommendations for molecular testing in melanoma
-
1:11
dr. hellmann on tumor mutational burden testing in patients with lung cancer
-
2:12
ctdna measurement via liquid biopsy: improving cancer detection and diagnosis
-
4:16
measuring tumor genes using cell-free dna - agbt 2015
-
4:09
quantum-r: quizartinib looks promising for flt3-itd mutated aml
-
0:55
challenges associated with biomarker testing for pd-l1 in nsclc
-
1:58
unanswered questions that remain in flt3-mutated aml